Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (19)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Chernajovsky, Y
Right arrow Articles by Maini, R N
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chernajovsky, Y
Right arrow Articles by Maini, R N
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

British Medical Bulletin 51:503-516 (1995)
© 1995 The British Council

research-article

Gene therapy of rheumatoid arthritis via cytokine regulation: future perspectives

Y Chernajovsky, M Feldmann and R N Maini

Kennedy Institute of Rheumatology Hammersmith, London, UK

Abstract

Following many years of research using isolated human tissues and animal models, sufficient knowledge concerning rheumatoid arthritis has accumulated so that novel immunotherapies have been proposed. Biological agents are being tested in clinical trials and include antibodies to T cells and cytokines. Currently the most promising of these is intravenously administered neutralizing anti-TNF antibody. In order to establish disease modification, however, therapy needs to be delivered continuously over the long term. The prospect of delivering cytokine inhibitors as genetic material (naked DNA), viruses or in engineered autologous cells is considered as one option for achieving this goal. We compare two strategies, firstly, using immobile cells such as fibroblasts, myoblasts or keratinocytes, and secondly, the migratory cells of the immune system. The former provides a reservoir of systemic delivery of the therapeutic protein whereas the latter provides targeted delivery determined by the antigen specificity of the immune cells. Early validation has begun in animal models of rheumatoid arthritis.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Immunol.Home page
J. M. Woods, K. J. Katschke Jr., M. V. Volin, J. H. Ruth, D. C. Woodruff, M. A. Amin, M. A. Connors, H. Kurata, K.-I. Arai, G. K. Haines III, et al.
IL-4 Adenoviral Gene Therapy Reduces Inflammation, Proinflammatory Cytokines, Vascularization, and Bony Destruction in Rat Adjuvant-Induced Arthritis
J. Immunol., January 15, 2001; 166(2): 1214 - 1222.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
G. A. Rabinovich, G. Daly, H. Dreja, H. Tailor, C. M. Riera, J. Hirabayashi, and Y. Chernajovsky
Recombinant Galectin-1 and Its Genetic Delivery Suppress Collagen-Induced Arthritis via T Cell Apoptosis
J. Exp. Med., August 2, 1999; 190(3): 385 - 398.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
B. Foxwell, K. Browne, J. Bondeson, C. Clarke, R. de Martin, F. Brennan, and M. Feldmann
Efficient adenoviral infection with Ikappa Balpha reveals that macrophage tumor necrosis factor alpha  production in rheumatoid arthritis is NF-kappa B dependent
PNAS, July 7, 1998; 95(14): 8211 - 8215.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.